Literature DB >> 17588966

Identification of suspected fatal adverse drug reactions by paediatricians: a UK surveillance study.

K Cheng1, S Masters, T Stephenson, R Cooke, R Ferner, M Ashworth, A J Nunn.   

Abstract

This British Paediatric Surveillance Unit (BPSU) study on adverse drug reactions (ADRs) in children was initiated because of concern that there might be under-reporting of serious ADRs in children using the yellow card scheme. We aimed to quantify the frequency of fatal ADRs in children under the age of 16 years in the United Kingdom and Ireland. The surveillance period ran for 13 months from June 2002 to June 2003, inclusive, and approximately 2000 cards were sent out monthly by the BPSU to consultant paediatricians in the United Kingdom and Ireland. In total, seven reports meeting the study criteria were received. Causality assessment was undertaken by an independent expert panel using formal, published criteria. In two of the deaths, the panel did not reach consensus and causality assessments varied from possible to certain. Five of the seven deaths were unanimously thought to be unlikely to be causally related to the index drug. Overall this study does not provide evidence of a major public-health concern relating to fatal ADRs in children. However, the limitations of the study mean that some fatal ADRs may have been unrecognised or unreported.

Entities:  

Mesh:

Year:  2007        PMID: 17588966     DOI: 10.1136/adc.2006.107789

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  2 in total

1.  Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis.

Authors:  Daniel B Hawcutt; Nicki-Jayne Russell; Hannah Maqsood; Koushan Kouranloo; Simon Gomberg; Catriona Waitt; Andrew Sharp; Andrew Riordan; Mark A Turner
Journal:  Br J Clin Pharmacol       Date:  2016-09-12       Impact factor: 4.335

2.  Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.

Authors:  A Aldea; M García Sánchez-Colomer; E Fernández Quintana; M García Sáiz
Journal:  Eur J Clin Pharmacol       Date:  2012-03-14       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.